Monday, August 17, 2026 See who Washington just made rich Go Pro · $40/mo →
Money Racket
Who Cashes In When Washington Moves
WHITE HOUSETrump Vaccine Spacing Order Reshapes Pharma DemandtodayENERGYMichigan's Line 5 Permit Renewal Is a Clear Win for Enbridge — and a Setback for Pipeline Opponents4 weeks agoHEALTHCARE & FDACMS Ends Medicare Part D Subsidy—Insurers Face PressuretodayHEALTHCARE & FDACMS's Site-Neutral and 340B Cuts Would Squeeze Hospital Systems and Hand Wins to Outpatient Rivals4 weeks agoTRADE & TARIFFSTariff Refunds Flow to Retailers—Earnings BoosttodayCRYPTOT. Rowe Price's Active Multi-Token Crypto ETF Is a Fee Story — and a Pressure Test for Bitwise and Grayscale4 weeks agoENERGYArmy Corps Permits Line 5 Tunnel—Michigan Blocks PathyesterdayWHITE HOUSEWhite House Cybersecurity Clearinghouse Creates a Direct Revenue Line for CrowdStrike, Palantir, and Microsoft4 weeks agoTRADE & TARIFFSTariff Refunds Turbocharge Retailer EarningsyesterdayWHITE HOUSEWhite House Control Over Frontier AI Access Reshapes the Pecking Order — Microsoft and Oracle Gain, Open-Source Loses4 weeks agoCRYPTOSEC Delays Crypto Rules—Uncertainty Persists2 days agoWHITE HOUSEWhite House Control Over Frontier AI Access Reshapes Who Wins the Model Race4 weeks agoTRADE & TARIFFSKimberly-Clark Pockets $45M Tariff Refund2 days agoHEALTHCARE & FDACMS's Site-Neutral and 340B Reform Proposal Squeezes Hospital Margins and Lifts Independent Pharmacies4 weeks agoTRADE & TARIFFSTrump Tariffs on Drones Boost U.S. Makers2 days agoDEFENSEU.S.-Iran Escalation and a Stalled Strait of Hormuz Are a Windfall for Tanker Owners and Defense Primes4 weeks agoHEALTHCARE & FDASimparica Trio Gets Screwworm EUA—Zoetis Wins3 days agoTECHBosch's $225M CHIPS Award for Silicon Carbide Chips Is a Direct Threat to Wolfspeed's U.S. Market Share4 weeks agoDEFENSEBlackSky Lands Multi-Year Satellite Contract3 days agoENERGYNew Mexico's Pipeline Denial Puts Oracle's Data Center Expansion on Ice — and Highlights Every Hyperscaler's Power Risk4 weeks agoTECHFCC Eases Broadband Label Rules—ISPs Win Flexibility4 days agoDEFENSEPentagon's $80M Drone Defense Contract Points to the Counter-UAS Names Worth Watching4 weeks agoDEFENSEIonQ Lands $28M U.S. Defense Quantum Contract4 days agoENERGYNew Jersey's Nuclear Energy Law Opens a Real Revenue Path for Small Reactor Developers4 weeks agoHEALTHCARE & FDAFDA Clears Screwworm Prevention Drug for U.S. Livestock5 days agoWHITE HOUSETrump's Defense Supply Chain Order Tightens Waiver Rules — Domestic Parts Makers Win, Foreign-Sourced Primes Face Friction4 weeks agoENERGYNRC Approves NAC MAGNASTOR Spent Fuel Storage Cask5 days agoDEFENSEU.S.-Iran Conflict Escalation Stalls Hormuz Shipping — Defense Contractors and Oil Majors Are the Immediate Read4 weeks agoHEALTHCARE & FDAFDA Updates Fresh-Cut Produce Safety Guidance5 days agoCRYPTOWhite House Concedes Ethics Provision in Crypto Bill — Clearing the Last Roadblock for Stablecoin Legislation4 weeks agoWHITE HOUSETrump Orders Childhood Vaccine Schedule Spacing5 days agoENERGYTrump's Saudi Nuclear Pact Without Enrichment Safeguards Heads to Congress — U.S. Uranium and Nuclear Services Names Are the Play4 weeks agoWHITE HOUSETrump Order Splits MMR Vaccine—Pharma Faces Demand Shift6 days agoWHITE HOUSETrump's Critical Minerals Order Cuts China Out of the Defense Supply Chain — and Sends Money to U.S. Miners4 weeks agoDEFENSETrump Pushes $1.5T Defense Budget—Lockheed, RTX, GD Lock in Gainslast weekTECHBosch's $225M CHIPS Act Award for Roseville Chips Away at U.S. Dependence on Asian Auto Semiconductors4 weeks agoWHITE HOUSEWhite House Drafts Vaccine-Autism Order—Pharma Faces Uncertaintylast weekHEALTHCARE & FDACMS Freezes $1 Billion in Medicaid Payments to California and Minnesota — Managed Care Insurers Face Revenue Gaps4 weeks agoTECHTrump Administration Adds 6 Chipmakers to U.S. Portfoliolast weekENERGYNRC Approves Holtec's Upgraded Spent Fuel Storage System — A Quiet Win for Nuclear's Capacity Expansion4 weeks agoDEFENSEPentagon Awards Space-Based Target Tracking Contractslast weekTRADE & TARIFFSTrump's 50% Canada Tariff Threat Keeps U.S. Aluminum Tight — Domestic Producers Win, Manufacturers Pay4 weeks agoENERGYMichigan Court Rejects Enbridge Line 5 Permit Under Great Lakeslast weekDEFENSEHouse Passes $1.15T Defense Bill — Missile Defense, Shipbuilding, and Next-Gen Air Get the Money4 weeks agoWHITE HOUSEDHS Tightens H-1B/L-1 Visa Fees—Tech Hiring Costs Rise for Employerslast weekDEFENSEOracle Lands a $7B Pentagon Software Contract — and the Market Should Take It Seriously3 weeks agoTECHU.S. Signs $874M Semiconductor Research LOIs—Chip Makers Get Federal Backinglast weekWHITE HOUSETrump's Critical Minerals Order Cuts China Out of the Military Supply Chain — These Miners Fill the Gap3 weeks agoTRADE & TARIFFSRetailers Sell Off Tariff Refund Rights for Cash—Windfall Monetized Before Payoutlast weekCRYPTOThe Senate's Landmark Crypto Bill Creates Winners Inside the ETF and Exchange Stack3 weeks agoHEALTHCARE & FDAFDA Approves Tudriqev for Advanced Melanomalast weekDEFENSEThe U.S.-Iran War Is Costing $37.5B and Counting — Here's Where That Money Goes3 weeks agoHEALTHCARE & FDAFTC Sues Hims & Hers Over Privacy and Billing Practiceslast weekENERGYTrump Signs the Saudi Nuclear Deal — and U.S. Uranium and Reactor Companies Are the Quiet Winners3 weeks agoMARKETSFTC Threatens Booking Holdings Over Priceline Practiceslast weekMARKETSChina's $765M Antitrust Fine on Trip.com Is a Warning Shot for U.S.-Listed Chinese Consumer Stocks3 weeks agoDEFENSERising Defense Spending Lifts Northrop Grumman Outlooklast weekHEALTHCARE & FDACMS's Star Ratings Overhaul Rescues the Biggest Medicare Advantage Insurers — For Now3 weeks agoTRADE & TARIFFSTrump Administration Hits $100B Tariff Refund Milestonelast weekTRADE & TARIFFSTariffs on Indian Pharma Are Coming — and U.S. Generic Drug Buyers Will Pay the Bill3 weeks agoHEALTHCARE & FDACMS Raises IRF Payments for 2027—Rehab Hospitals Get Relieflast weekDEFENSEPentagon's $7B Oracle Software Deal Is One of the Cleanest Defense-Tech Wins in Years3 weeks agoHEALTHCARE & FDACMS Ends Medicare Part D Subsidy—Drug Plan Insurers Face Margin Pressurelast weekDEFENSEPentagon Awards Oracle $7B Software Consolidation Deal—Direct Win for Oracle, Pressure on Smaller Defense IT Rivals3 weeks agoHEALTHCARE & FDAHHS Boosts Hospital Payments by $2 Billion—Acute Care Operators Winlast weekTECHFCC Tightens Submarine Cable Licensing Rules—Tech Giants Face New Compliance Costs, Telecom Carriers Gain Regulatory Clarity3 weeks agoTRADE & TARIFFSAmazon Pockets $600M Tariff Refund—Retail Rivals Face Margin Squeezelast weekHEALTHCARE & FDACMS Overhauls Medicare Advantage Star Ratings—UnitedHealth, Humana, and Anthem Positioned to Gain from Simplified Metrics3 weeks agoENERGYMichigan Court Vacates Line 5 Permit—Enbridge Faces Shutdown Risklast weekDEFENSEHouse Passes $1.15 Trillion Defense Bill—Lockheed, Raytheon, and General Dynamics Positioned for Record Spending3 weeks agoHEALTHCARE & FDAHumana Exits MA Markets—600K Members Face Plan Disruption2 weeks agoDEFENSEPentagon Awards Oracle $7B Software Consolidation Deal—Largest Defense IT Overhaul in Years3 weeks agoWHITE HOUSETrump Blocks Critical Minerals Exports—U.S. Miners Get Protected Market2 weeks agoDEFENSERocket Lab Wins $266M Space Force Contract—Suborbital Launch Capability Becomes Defense Asset3 weeks agoDEFENSEHouse Passes $95B Iran War Package—Defense Contractors Lock in Revenue2 weeks agoHEALTHCARE & FDACMS Overhauls Medicare Advantage Star Ratings—Big Insurers Win, Quality Metrics Tighten3 weeks agoHEALTHCARE & FDAFDA Revokes Petroleum-Based Food Dyes—Natural Color Makers Win2 weeks agoDEFENSERocket Lab Wins $266M Space Force Missile Defense Contract—Suborbital Launch Niche Gets Federal Validation3 weeks agoTECHCommerce Awards $874M in Semiconductor R&D LOIs—Chip Makers Get Federal Backing2 weeks agoDEFENSEPentagon Awards Oracle $7B Software Consolidation Deal—Cloud Incumbents Face Pressure, Oracle Locks in Defense Revenue3 weeks agoTRADE & TARIFFSAmazon Gets $600M Tariff Refund—Retailers Lift Guidance on Windfall2 weeks agoCRYPTOSEC Settles Coinbase FOIA Suit Over Missing Gensler Texts—Crypto Compliance Pressure Eases, Coinbase Stock Gains Clarity3 weeks agoSEARCH DEMANDData Center Power Exchange2 weeks agoHEALTHCARE & FDACMS Stars Redo Lifts Medicare Advantage Insurers—Rating System Overhaul Favors UnitedHealth, Humana, Anthem3 weeks agoSEARCH DEMANDCasgevy List Price: $2.2 Million2 weeks agoDEFENSEPentagon Awards Largest F-35 Spare Parts Contract—Lockheed Locks in Sustainment Revenue3 weeks agoENERGYPHMSA Updates Pipeline Safety Standards—Compliance Costs Hit Operators, Benefit Inspectors2 weeks agoDEFENSEHouse Passes $1.15T Defense Bill—Lockheed, Raytheon, General Dynamics Lock in Revenue2 weeks agoMARKETSSEC Explores 23-Hour Stock Trading—Market Makers and Tech Platforms Get New Revenue2 weeks ago
That's your last free article this week. Create a free account for 4 a week — or go Pro for everything.Go Pro →
Healthcare & FDA

Medicare Starts Covering GLP-1 Weight-Loss Drugs July 1 — Novo Nordisk and Eli Lilly Just Got 67 Million New Potential Customers

Federal coverage of Wegovy and similar drugs through Medicare is the single largest demand expansion in the GLP-1 market's history.

Image: Money Racket
By at Money Racket · Jul 3, 2026
1-YEAR MOVE
+45% −37%
NVO ▼14.3% LLY ▲43.0%
1-year price move by ticker
TickerCompany1-year change
NVONovo Nordisk−14.3%
LLYEli Lilly+43.0%

Medicare began covering weight-loss drugs including Wegovy for eligible beneficiaries on July 1, 2026, through a GLP-1 Bridge program, according to CNN and Pharmaceutical Executive. This marks the first time Medicare has covered drugs specifically for weight loss, opening the program's roughly 67 million enrollees to these therapies.

Medicare coverage of GLP-1s is not incremental — it is the largest single expansion of the addressable market these drugs have ever seen.

Who cashes in: Novo Nordisk NVO makes Wegovy (semaglutide) and is the most direct beneficiary — Medicare coverage removes the single biggest access barrier for the drug's largest potential patient cohort. Eli Lilly LLY makes Zepbound (tirzepatide), the competing GLP-1 that will also be eligible; both companies stand to see volume increases that dwarf anything the commercial market has delivered. The supply chain behind these drugs also benefits: West Pharmaceutical Services WST and Gerresheimer (private/German) make the injectable delivery systems, and Catalent (now part of Novo's supply chain) handles fill-finish manufacturing. On the plastics and packaging side, Plastics News has flagged a manufacturing boost for GLP-1 production components.

Who's exposed: The Trump administration has separately proposed a rule it says could save Medicare patients $1.1 billion on drugs — if that rule includes GLP-1 pricing pressure, it could compress the net revenue per prescription even as volume rises. Compounding pharmacies that have been filling semaglutide during the shortage period face a more competitive landscape as branded supply expands to meet Medicare demand. Weight-loss surgery providers and bariatric device makers like Intuity Medical face long-term volume pressure as pharmacological alternatives become more accessible.

What to watch: CMS reimbursement rates for GLP-1s under Medicare Part D and whether the proposed drug-pricing rule applies to this class. The rate set by CMS will determine how much of the volume gain actually flows to Novo and Lilly's bottom lines.

Source: original report ↗

Free alerts

Free: catalyst alerts, straight to your inbox.

Get the White House orders, federal contracts, and FDA decisions that move money — with who cashes in — free. Unsubscribe in one click.

Free · weekly · unsubscribe anytime. Privacy.

Stay three moves ahead of every practice in your market.

Knowing it happened is table stakes. Money Racket Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.

Get the edge · $40/mo

Join the owners who run ahead of the industry. Cancel anytime, one click.

Share

https://moneyracket.com/article/medicare-glp1-coverage-novo-eli-lilly-wegovy/

Discussion

    Leave a comment

    Comments are reviewed before they appear.
    Money Racket Pro

    By the time it's news, the money's already moved.

    The contract award, the executive order, the tariff cut — it mints winners before the financial press connects the dots. Pro gets you there first: what happened, who cashes in, and exactly what to watch — in a two-minute read.

    Go Pro · $40/mo The policy-to-profit brief. Cancel anytime.
    The pre-market brief · Mon–Sat, 7:45am ET Go Pro · $40/mo →